HSV1&2 VZV R-GENE ®

REAL TIME PCR ASSAYS - ARGENE® TRANSPLANT RANGE

The power of true experience

 HSV1&2 VZV R-GENE®
KEY FEATURES CLINICAL CONTEXT 1-5
• Ready-to-use reagents Herpes Simplex Viruses (HSV) 1 and 2 and Varicella-Zoster
Virus (VZV) are DNA viruses belonging to the Herpesviridae
• Complete qualitative and quantitative kit family. Primary infection is generally limited to the mucous
• Simultaneous detection and quantification of membranes and the skin. After primary infection, the virus
HSV1 and HSV2 persists in the host by establishing a latent infection. In case
• Detection and quantification of VZV of chronic or transient immunosuppression, the virus may
reactivate to generate recurrent infection. Usually benign,
• Validated on most relevant sample types
08/19 9317227 007/GB/A / BIOMÉRIEUX, the BIOMÉRIEUX logo, ARGENE, EMAG, easyMAG, NUCLISENS and R-GENE are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies.

the infections with these viruses can develop in severe

• V alidated with the major extraction and clinical forms such as encephalitis, meningitis, retinitis,
amplification platforms fulminant hepatitis, bronchopneumonia and neonatal infections.
• D esigned for low to high throughput analysis Various antivirals have proven their efficacy in treating these pathologies when
•Same procedure for all the ARGENE® prescribed early and at appropriate doses. In case of severe infections, it is therefore
Transplant kits essential to obtain an early and rapid diagnosis of the infection.

TECHNICAL INFORMATION
ORDERING INFORMATION HSV1&2 VZV R-GENE® - Ref. 69-014B
Parameters HSV1 HSV2 VZV
Gene target US7 UL27 gp19 protein
CSF, Whole blood, Plasma, BAL, CSF, Whole blood, Plasma,
Mucocutaneous swabs (qualitative BAL , Mucocutaneous swabs CSF, Whole blood, Plasma,
Validated
only), Anogenital swabs (qualitative (qualitative only), Anogenital swabs Mucocutaneous swabs
specimens
only), Throat swabs (qualitative (qualitative only), Throat swabs (qualitative only)
Any other name or trademark is the property of its respective owner / bioMérieux S.A. RCS Lyon 673 620 399 / Printed in France / thera / RCS Lyon B 398 160 242

only) (qualitative only)

CSF: 2.4 log10 copies/mL CSF: 2.0 log10 copies/mL CSF: 2.5 log10 copies/mL
Limit of Detection Whole Blood, Plasma, BAL: Whole Blood, Plasma, BAL: Whole Blood, Plasma:
(LoD 95%) 2.7 log10 copies/mL 2.0 log10 copies/mL 2.7 log10 copies/mL
Swabs: 3.0 log10 copies/mL Swabs: 3.0 log10 copies/mL Swabs: 3.0 log10 copies/mL

CSF: 2.4 log10 to 8.0 log10 copies/mL CSF: 2.0 log10 to 8.0 log10 copies/mL CSF: 2.7 log10 to 8.0 log10 copies/mL
Quantification Range Whole blood, Plasma, BAL : Whole blood, Plasma, BAL: Whole blood, Plasma :
2.7 log10 to 8.0 log10 copies/mL 2.7 log10 to 8.0 log10 copies/mL 2.7 log10 to 8.0 log10 copies/mL
Type of kit Real-time detection and quantification kit
Validated extraction platforms EMAG®, NUCLISENS® easyMAG®, MagNA Pure 96, QIAsymphony SP
Validated amplification
ABI 7500 Fast, ABI 7500 Fast Dx, LightCycler 480 (System II), Rotor-Gene Q, CFX96
platforms
Extraction / Inhibition Control, Negative Control, Positive Control (QS3), 4 Quantification Standards,
Controls included
Sensitivity Control
Same PCR program as other ARGENE® Transplant kits
PCR Protocol
Same PCR program as ENTEROVIRUS R-GENE® and Parechovirus R-GENE®
Number of tests 60 tests for HSV1&2, 60 tests for VZV
Storage conditions -15°C / -31°C
Regulatory status For in vitro diagnostic use, CE-IVD marking

OTHER ARGENE® TRANSPLANT KITS OTHER ARGENE® KITS

• EBV R-GENE® (69-002B) • CMV R-GENE® (69-003B) • HHV6 R-GENE® (69-006B) • ENTEROVIRUS R-GENE® (69-005B)
• ADENOVIRUS R-GENE® (69-010B) • BK Virus R-GENE® (69-013B) • Parvovirus B19 • Parechovirus R-GENE® (71-020)
R-GENE® (69-019B) • HSV1 HSV2 R-GENE® (71-021) • VZV R-GENE® (71-022)

REFERENCES
1. Kumar et al. Pathogenesis and life cycle of herpes simplex virus infection-stages of primary, latency and recurrence. Journal of Oral and Maxillofacial Surgery, Medecine, and Pathology 2016; 28: 350-353
2. Zerboni et al. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014; 12(3): 197-210
3. Burrel S, Boutolleau D. Virus herpes simplex. EMC – Maladies infectieuses 2014; 11(4): 1-19
4. Widener et al. Herpes simplex virus. Handbook of Clinical Neurology 2014; 123(11): 251-263
5. Wang et al. Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Litterature. Front Immunol 2018; 9(1632) : 1-11

bioMérieux S.A. • 69280 Marcy l’Etoile • France • Tél.: + 33 (0)4 78 87 20 00 • Fax: +33 (0)4 78 87 20 90
www.biomerieux.com